Contributions: Drs. CW Su and CY Wu contributed equally to this work.
Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy
Version of Record online: 22 NOV 2013
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Volume 28, Issue 12, pages 1849–1858, December 2013
How to Cite
Su, C.-W., Wu, C.-Y., Hung, H.-H., Wu, C.-H., Sheen, I.-J. and Wu, J.-C. (2013), Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. Journal of Gastroenterology and Hepatology, 28: 1849–1858. doi: 10.1111/jgh.12283
Disclosures: The authors have no potential conflicts (financial, professional, or personal) of interest.
Grant Support: This study was supported by grants from the National Science Council of Taiwan (NSC 101–2314-B-075-013-MY2), Taipei Veterans General Hospital (V95C1-014, VGHUST100-G7-2-1), Yang-Ming University (101AC-T501, Ministry of Education, Aim for the Top University Plan), and the Center of Excellence for Cancer Research at TVGH (DOH101-TD-C-111-007, DOH102-TD-C-111-007), Taipei, Taiwan.
Writing assistance: Gene Alzona Nisperos MD.
- Issue online: 22 NOV 2013
- Version of Record online: 22 NOV 2013
- Accepted manuscript online: 4 JUN 2013 05:09AM EST
- Manuscript Accepted: 15 MAY 2013
- National Science Council of Taiwan. Grant Number: NSC 101–2314-B-075-013-MY2
- Taipei Veterans General Hospital. Grant Numbers: V95C1-014, VGHUST100-G7-2-1
- Yang-Ming University. Grant Number: 101AC-T501
- Center of Excellence for Cancer Research at TVGH. Grant Number: DOH101-TD-C-111-007
Figure S1 The impact of baseline serum HBsAg levels on HBV DNA virological breakthrough among patients with HBeAg-negative chronic hepatitis B who received lamivudine therapy. (a) The cumulative virological breakthrough rates were similar between patients with baseline HBsAg levels ≥ 2000 IU/mL and those with < 2000 IU/mL (P = 0.905). (b) Among patients with serum HBV DNA < 2000 IU/mL at 6 months post-therapy, the cumulative virological breakthrough was comparable between patients with baseline HBsAg levels ≥ 2000 IU/mL and those with < 2000 IU/mL in HBeAg-negative patients (P = 0.761).
Table S1 Comparison of demographic data between patients infected with genotype B and C HBV.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.